银屑病关节炎中新型生物制剂和靶向合成改善病情抗风湿药的 uptake 与有效性:来自五个北欧生物制剂登记的研究结果
研究纳入五个北欧风湿病登记中2012-2020年启动b/tsDMARD的银屑病关节炎患者,描述新型b/tsDMARD的 uptake 并比较其保留率和有效性。阿达木单抗更多用作第一疗程,新型b/tsDMARD更多用于生物制剂经治患者。作为第二/三疗程时,阿达木单抗的保留率和LDA达标比例显著优于阿巴西普、阿普米司特、依奇珠单抗和乌司奴单抗。
要点
- 新型b/tsDMARD的 uptake 从2014年增加,2018年趋于平稳。
- 作为第二/三疗程,阿达木单抗保留率65%、LDA比例59%,优于阿巴西普45%、37%。
- 无论作用机制,启动第二或以后b/tsDMARD疗程的患者仅少数维持用药并达到LDA。
核心结论
- 新型b/tsDMARD的 uptake 主要发生在生物制剂经治患者中。
- 无论作用机制,启动第二或以后b/tsDMARD疗程的患者仅少数维持用药并达到LDA。
- 阿达木单抗的结局更优,表明新型b/tsDMARD在PsA治疗流程中的定位尚待确立。
研究设计与样本
- 五个北欧风湿病登记中2012-2020年启动b/tsDMARD的银屑病关节炎患者被纳入。
- 共纳入5659个阿达木单抗疗程(56%为生物制剂初治)和4767个新型b/tsDMARD疗程(21%为生物制剂初治)。
- 通过链接国家患者登记识别合并症,采用按治疗疗程分层的校正回归模型比较新型b/tsDMARD与阿达木单抗的1年保留率和6个月有效性。
主要发现
- 新型b/tsDMARD的 uptake 从2014年增加,2018年趋于平稳。
- 治疗开始时各治疗间患者特征似乎相似。
- 阿达木单抗更常作为第一疗程使用,新型b/tsDMARD更常用于生物制剂经治患者。
- 作为第二/三疗程b/tsDMARD,阿达木单抗的保留率65%、LDA比例59%,显著优于阿巴西普45%、37%,阿普米司特43%、35%,依奇珠单抗(仅LDA)40%和乌司奴单抗(仅LDA)40%,与其他b/tsDMARD无显著差异。
关键数值与推荐
- 作为第二/三疗程,阿达木单抗保留率65% vs 阿巴西普45%,LDA比例59% vs 37%。
- 作为第二/三疗程,阿达木单抗LDA比例59% vs 阿普米司特35%。
- 作为第二/三疗程,阿达木单抗LDA比例59% vs 依奇珠单抗40%(仅报告LDA)。
- 作为第二/三疗程,阿达木单抗LDA比例59% vs 乌司奴单抗40%(仅报告LDA)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to describe the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the Nordic countries and to compare their retention and effectiveness. METHODS: Patients with PsA starting a b/tsDMARD in 2012-2020 in five Nordic rheumatology registers were included. Uptake and patient characteristics were described, with comorbidities identified from linkages to national patient registries. One-year retention and 6-month effectiveness (proportions achieving low disease activity (LDA) on the Disease Activity Index for PSoriatic Arthritis based on 28-joint evaluation) for the newer b/tsDMARDs (abatacept/apremilast/ixekizumab/secukinumab/tofacitinib/ustekinumab) were compared with adalimumab through adjusted regression models stratified by treatment course (first, second/third, and fourth or more). RESULTS: In total, 5659 treatment courses with adalimumab (56% biologic-naïve) and 4767 courses with a newer b/tsDMARD (21% biologic-naïve) were included. The uptake of newer b/tsDMARDs increased from 2014 and plateaued in 2018. Patient characteristics appeared similar across treatments at treatment start. Adalimumab was more often used as the first course and newer b/tsDMARDs more often in biologic-experienced patients. Used as a second/third b/tsDMARD, the retention rate and the proportion achieving LDA were significantly better for adalimumab (rate 65%, proportion 59%) compared with abatacept (45%, 37%), apremilast (43%, 35%), ixekizumab (LDA only, 40%) and ustekinumab (LDA only, 40%), but not significantly different from other b/tsDMARDs. CONCLUSION: Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA. Superior outcomes for adalimumab indicate that the positioning of newer b/tsDMARDs in the PsA treatment algorithm remains to be established.
引用
- Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023. PMID: 36813538. doi:10.1136/ard-2022-223650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。